Podcast
Episode 105 — Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits
November 24, 2025
Latham and EY’s Eliza Biedziak discuss what to expect from a government pricing assessment, the role assessments play in compliance, and how assessments can uncover strategic opportunities.
Government pricing assessments are an important tool to help pharmaceutical manufacturers review their government price reporting function, but they can also help uncovering strategic benefits and opportunities. In this episode of Connected With Latham, Eliza Biedziak, Managing Director at EY, joins Washington, D.C. partner Chris Schott and associate Danny Machado to explore how these assessments are conducted, the compliance benefits they offer, and the strategic insights they can provide.
Listen here or subscribe via Apple Podcasts, Spotify, or anywhere else you listen to podcasts.
Read our bi-weekly Drug Pricing Digest or subscribe to receive future editions in your inbox.